A unique opportunity

HaemaLogiX focuses on developing and commercialising novel immuno-oncology and immune therapies. HaemaLogiX acquired the business assets of Immune System Therapeutics and is embarking on several interrelated research and clinical development projects that will validate our antigen targets and products. We have a unique opportunity to develop effective treatments that improve the quality of life of patients suffering from blood cancers and autoimmune diseases.

Two novel drug targets - Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) - have been identified on the surface of human blood cancer and autoimmune cells. These targets are highly specific to abnormal B-cells and have been identified in blood cancers such as multiple myeloma (MM), lymphoma and Waldenstrom's macroglobulinemia.

Read More